Published in Cardiovasc Drugs Ther on June 01, 1990
A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol (1970) 2.78
The preexcitation syndromes. Prog Cardiovasc Dis (1978) 2.23
Effect of amiodarone in the Wolff-Parkinson-White syndrome. Am J Cardiol (1976) 1.41
Electrophysiological effects of sotalol--just another beta blocker? Br Heart J (1982) 1.13
Sotalol, hypokalaemia, syncope, and torsade de pointes. Br Heart J (1984) 1.13
Effect of drugs in the Wolff-Parkinson-White syndrome. Importance of initial length of effective refractory period of the accessory pathway. Am J Cardiol (1980) 1.12
Prolongation of the human cardiac monophasic action potential by sotalol. Am J Cardiol (1982) 1.05
Acute prolongation of myocardial refractoriness by sotalol. Br Heart J (1982) 0.97
Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil. Circulation (1982) 0.91
Differential effects of sotalol and metoprolol on induction of paroxysmal supraventricular tachycardia. Am J Cardiol (1984) 0.91
Temporal relation between long-lasting aftercontractions and action potentials in cat papillary muscles. Science (1968) 0.84
Acute and chronic effects of sotalol and propranolol on ventricular repolarization using constant-rate pacing. Am J Cardiol (1986) 0.83
Electropharmacology of sotalol in patients with Wolff-Parkinson-White syndrome. Circulation (1987) 0.81
Sotalol, prolonged Q-T interval, and ventricular tachyarrhythmias. Ann Clin Res (1981) 0.78
Effect of Sotalol on clinical arrhythmias. Am J Cardiol (1972) 0.76
Effect of propranolol on ventricular rate during atrial fibrillation in the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol (1987) 0.76